A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months

Status: Recruiting
Location: See all (19) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 52-week period.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 3
Healthy Volunteers: f
View:

• Participants must be 0 to \< 36 months of age at randomization.

• Participants must have a confirmed genetic diagnosis of HCH (obtained via whole genome sequencing; presence of a FGFR3 pathogenic variant associated with HCH).

• Participants aged 0 to \< 12 months must have a height Z-score of ≤ -1.0 SDS andparticipants aged ≥ 12 to \< 36 months must have a height Z-score of ≤ -2.0 SDS in reference to the average stature of the same sex and age, as calculated using the Center for Disease Control and Prevention (CDC) growth charts.

• Participant's weight at the Day 1 visit (pre-treatment) must be ≥ 3 kg.

Locations
United States
Arizona
Phoenix Children's Hospital - Thomas Campus (Main)
NOT_YET_RECRUITING
Phoenix
California
Cedars-Sinai Medical Center
NOT_YET_RECRUITING
Los Angeles
Benioff Children's Hospital - Oakland
NOT_YET_RECRUITING
Oakland
Washington, D.c.
Children's National Medical Center
RECRUITING
Washington D.c.
Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago
NOT_YET_RECRUITING
Chicago
Maryland
The Johns Hopkins University School of Medicine
NOT_YET_RECRUITING
Baltimore
Minnesota
University of Minneasota Masonic Children's Hospital
NOT_YET_RECRUITING
Minneapolis
Missouri
University of Missouri
NOT_YET_RECRUITING
Columbia
Wisconsin
Children's Wisconsin - Fox Valley Hospital
NOT_YET_RECRUITING
Neenah
Other Locations
Australia
Royal Children's Hospital Melbourne
NOT_YET_RECRUITING
Parkville
France
Hospices Civils de Lyon - Hôpital Femme Mère Enfant
NOT_YET_RECRUITING
Bron
Hôpital Bicêtre
NOT_YET_RECRUITING
Le Kremlin-bicêtre
Germany
Uniklinik Köln
NOT_YET_RECRUITING
Cologne
Universitätsklinikum des Saarlandes
NOT_YET_RECRUITING
Homburg
Universitätskinderklinik Magdeburg
NOT_YET_RECRUITING
Magdeburg
Italy
IRCCS Istituto Giannina Gaslini
NOT_YET_RECRUITING
Genova
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NOT_YET_RECRUITING
Roma
United Kingdom
Great Ormond Street Hospital
NOT_YET_RECRUITING
London
Myriad Trials
NOT_YET_RECRUITING
London
Contact Information
Primary
Trial Specialist
medinfo@bmrn.com
1-800-983-4587
Time Frame
Start Date: 2025-07-30
Estimated Completion Date: 2028-06-30
Participants
Target number of participants: 60
Treatments
Experimental: Vosoritide injection with vial and syringe
Subcutaneous injection of recommended dose of vosoritide based on weight-band dosing once daily.
Placebo_comparator: Placebo injection with vial and syringe
Subcutaneous injection of recommended dose of placebo
Related Therapeutic Areas
Sponsors
Collaborators: ICON Clinical Research
Leads: BioMarin Pharmaceutical

This content was sourced from clinicaltrials.gov